{"id":"W2991616458","doi":"10.1093/annonc/mdz296","title":"EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":182,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"Cilag; Pharmacyclics; Chugai Pharmaceutical; MSD Australia; EMD Serono; Genentech; Active Biotech; Medac; Ipsen; Bavarian Nordic; Shionogi; Astellas Pharma; Eisai; European Society for Medical Oncology; European Association of Urology; Sirtex Medical; Cancer Research UK; GlaxoSmithKline; UroGen Pharma; Pfizer; Incyte; Manchester Biomedical Research Centre; Accuray; National Institute for Health and Care Research; Clovis Oncology; Teva Pharmaceutical Industries; Les Laboratories Pierre Fabre; Celldex Therapeutics; Siemens Healthineers; Amgen; Elekta; Sanofi Pasteur; Royal Marsden NHS Foundation Trust; Alere; Bayer HealthCare; Exelixis; Sanofi; Endocyte; Novartis; Bayer; Allergan; AstraZeneca; Associazione Italiana per la Ricerca sul Cancro; Eli Lilly and Company","keywords":"Medicine; Delphi method; Stakeholder; Delphi; Bladder cancer; Voting; Consensus conference; Family medicine; Cancer; Public relations; Internal medicine; Political science","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.2761936,0.001471134,0.001530035,0.007004608,0.003353877,0.00394415,0.003506935,0.005514306,0.005347206],"category_scores_gemma":[0.2021054,0.0009809495,0.002292482,0.005423422,0.002624826,0.004611156,0.01459209,0.004244829,0.00154849],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.005191756,"about_ca_system_score_gemma":0.05877078,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003271883,"about_ca_topic_score_gemma":0.003887407,"domain_scores_codex":[0.7709543,0.1782783,0.01867563,0.003863097,0.02245324,0.005775521],"domain_scores_gemma":[0.7519633,0.08040187,0.01886235,0.01060411,0.1168971,0.02127124],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001371031,0.001435822,0.02267286,0.01241071,0.0005920371,0.002169282,0.07329945,0.005070633,0.01138227,0.01768166,0.2085609,0.6433533],"study_design_scores_gemma":[0.0007731878,0.001903209,0.06908034,0.0448763,0.0005585751,0.004385187,0.09775314,0.01519406,0.01103311,0.04292493,0.7108603,0.0006576567],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"methods","genre_gemma":"editorial","genre_scores_codex":[0.2393565,0.02996447,0.3769225,0.18769,0.0106389,0.07863721,0.003730102,0.001385892,0.0716744],"genre_scores_gemma":[0.405561,0.009547246,0.5164583,0.01406358,0.001270366,0.03584502,0.003930858,0.0004254584,0.01289817],"genre_candidate":"editorial","genre_consensus":null,"teacher_disagreement_score":0.2761936,"threshold_uncertainty_score":0.8925821,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1653293173419298,"score_gpt":0.4504202926011262,"score_spread":0.2850909752591964,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}